The World Market for Pain Management Drugs and Devices
The World Market for Pain Management Drugs and Devices encompasses a wide variety of products that treat and ease pain. The field of pain management is currently experiencing a busy and interesting period; and as a result, the range of therapeutic options available to physicians and other clinicians has expanded. Solutions to pain disorders are still elusive but continued human and animal studies will help to further identify the biochemical and neurophysiological factors that influence pain. The future of pain management will likely involve multidisciplinary departments dedicated to finding treatments that manage pain. The need is great worldwide for management of pain and there are still many facets of pain management that need to be explored.
Faced with intensifying competition and increasingly price sensitive markets, manufacturers in the area of pain management therapeutics are trying to differentiate their products to avoid price competition and to increase profits. However, there are a number of issues and trends that have a direct influence on this market and the manufacturer’s ability to successfully operate in the market. A keen awareness of all facets of the industry including barriers will enable manufacturers to effectively challenge these issues and formulate plans to reduce or eliminate barriers in the treatment of pain.
The driving forces for this market include growth and aging of the global population, new products and technology, and increasing interest in multidisciplinary approaches to pain management.
This report, The World Market for Pain Management Drugs and Devices, provides market estimates and forecasts for the following therapeutic categories:
The information and analysis presented in this report are based on extensive interviews with senior management of top companies and conference participants (business and clinical) in the pain management market. Background information was obtained from a comprehensive search of published literature and reports obtained from various government, business, medical trade, and international journals. Key information from published literature was used to conduct interviews with over 45 industry executives and product managers to validate and obtain expert opinion on current and future trends in the pain management market. Interviews were also used to confirm and/or adjust market size estimates, as well as in formulating market projections.
All market data pertain to the world market at the manufacturers’ level. Data are expressed in current U.S. dollars. The base year for data was 2012. Historical data is provided for 2010 and 2011, and forecast data are provided for each of the years 2012 through 2017. Historical, base year, and forecast data are provided for each market segment. Market shares are provided for each market segment for the 2012 base year.
Top product revenues are considered for the report in each subsegment according to treatment use. Top products in each category represent approximately 80% of the total revenues for each subsegment. The total market reflects the total revenues of all top products in all of the individual categories, representing approximately 80%-90% of the total prescription pain management pharmaceuticals and pain management devices.
As part of the study the following competitors are profiled:
Faced with intensifying competition and increasingly price sensitive markets, manufacturers in the area of pain management therapeutics are trying to differentiate their products to avoid price competition and to increase profits. However, there are a number of issues and trends that have a direct influence on this market and the manufacturer’s ability to successfully operate in the market. A keen awareness of all facets of the industry including barriers will enable manufacturers to effectively challenge these issues and formulate plans to reduce or eliminate barriers in the treatment of pain.
The driving forces for this market include growth and aging of the global population, new products and technology, and increasing interest in multidisciplinary approaches to pain management.
This report, The World Market for Pain Management Drugs and Devices, provides market estimates and forecasts for the following therapeutic categories:
- Burn Pain
- Cancer Pain
- Dental/Facial Pain
- Migraine Headache Pain
- Musculoskeletal Pain
- Neuropathic Pain
- Obstetrical Pain
- Pediatric Pain
- Surgical and Trauma Pain
The information and analysis presented in this report are based on extensive interviews with senior management of top companies and conference participants (business and clinical) in the pain management market. Background information was obtained from a comprehensive search of published literature and reports obtained from various government, business, medical trade, and international journals. Key information from published literature was used to conduct interviews with over 45 industry executives and product managers to validate and obtain expert opinion on current and future trends in the pain management market. Interviews were also used to confirm and/or adjust market size estimates, as well as in formulating market projections.
All market data pertain to the world market at the manufacturers’ level. Data are expressed in current U.S. dollars. The base year for data was 2012. Historical data is provided for 2010 and 2011, and forecast data are provided for each of the years 2012 through 2017. Historical, base year, and forecast data are provided for each market segment. Market shares are provided for each market segment for the 2012 base year.
Top product revenues are considered for the report in each subsegment according to treatment use. Top products in each category represent approximately 80% of the total revenues for each subsegment. The total market reflects the total revenues of all top products in all of the individual categories, representing approximately 80%-90% of the total prescription pain management pharmaceuticals and pain management devices.
As part of the study the following competitors are profiled:
- Abbott Laboratories
- Actavis, Inc (formerly Watson Pharmaceuticals, Inc.)
- AstraZeneca plc.
- Baxter International, Inc.
- BioDelivery Sciences International (BDSI)
- Boehringer Ingelheim
- Boston Scientific
- Bristol-Myers Squibb Company
- DepoMed
- DURECT Corporation
- Eli Lilly & Co.
- Endo Health Solutions Inc
- GlaxoSmithKline plc
- Grunenthal Group
- Medtronic, Inc.
- Merck & Co.
- Novartis
- Pain Therapeutics, Inc
- Pfizer, Inc
- Purdue Pharma
- QRx Pharma
- Sanofi
- St. Jude Medical, Inc
- TEVA Pharmaceuticals Industries, Ltd
- The Medicines Company
- Valeant Pharmaceuticals International, Inc.
- Zogenix, Inc.
CHAPTER ONE: EXECUTIVE SUMMARY
Introduction
Scope and Methodology
Size and Growth of the Market
Issues and trends
Leading Competitors
CHAPTER TWO: INTRODUCTION AND OVERVIEW
Definition of Pain
Magnitude of Pain
Physiology of Pain
Transduction
Transmission
Pain Pathways
Types of Pain
Measurement of Pain
Treatment Modalities—Pharmacologic Management
Analgesic Ladder
Step I Drugs
Step II Drugs
Step III Drugs
Recommended Drug and Route
Administration Routes
Titration
Treatment Modalities—Non-pharmacologic Management
Cognitive-Behavioral Therapies
Multidisciplinary Pain Management
Demographics
CHAPTER THREE: TREATMENT MARKETS AND FORECASTS
Burn Pain
Overview of Top Products
Opiate Agonists—Natural Alkaloids
Opiate Agonists—Semisynthetic Analogs
Opiate Agonists—Synthetic Compounds
Market Size and Growth
Markets by Region
Cancer Pain
Breakthrough Cancer Pain
Overview of Top Products
Opiate Agonists- Natural Alkaloids
Opiate Agonists-Semisynthetic Analogs
Opiate Agonists- Synthetic Compounds
Phenylpiperdine Compounds
New and/or Innovative Products
Market Size and Growth
Markets by Region
Dental/Facial Pain
Overview of Top Products
Opiate Agonists- Natural Alkaloids
Opiate Agonists-Semisynthetic Analogs
Opiate Agonists- Synthetic Compounds
Opiate Agonist-Antagonists
Centrally-acting Synthetic Analgesic Compounds
New Products
Market Size and Growth
Markets by Region
Migraine Headache Pain
Overview of Top Products
Selective Serotonin Agonists
New and/or Innovative Products
Market Size and Growth
Markets by Region
Musculoskeletal Pain
Overview of Top Products
Phenylpiperidine Compounds
Cox-2 Inhibitors
Non-steroid Anti-inflammatory Drugs
Opioid Agonists- Natural Alkaloids
Hyaluronate Sodium Derivative
New and/or Innovative Products
Market Size and Growth
Markets by Region
Neuropathic Pain
Overview of Top Products
Antiseizure Drugs
Opiate Agonists- Natural Alkaloids
Opiate Agonists-Semi-Synthetic Analogs
Phenylpiperidine Compounds
New and/or Innovative Products
Market Size and Growth
Markets by Region
Obstetrical Pain
Overview of Top Products
Opiate Agonists—Synthetic Compounds
Opiate Agonist—Antagonists
Centrally Acting Synthetic Analgesic Compounds
Phenylpiperidine Compounds
Market Size and Growth
Markets by Region
Pediatric Pain
Overview of Top Products
Opiate Agonist-Antagonists
Indole Analogs
Opiate Agonists-Semisynthetic Analogs
Opiate Agonists- Natural Alkaloids
Market Size and Growth
Markets by Region
Surgical and Trauma Pain
Overview of Top Products
Opiate Agonists—Natural Alkaloids
Opiate Agonists—Semisynthetic Analogs
Opiate Agonists—Synthetic Compounds
Opiate Agonist—Antagonists
Centrally Acting Synthetic Analgesic Compounds
New and/or Innovative Product Approvals
Market Size and Growth
Markets by Region
CHAPTER FOUR: DRUG DELIVERY
Oral Drug Delivery
Parenteral Drug Delivery
Transdermal
Patient Controlled Analgesia
Intrathecal Implants
Electrotransport Drug Delivery
CHAPTER FIVE: PAIN MANAGEMENT DEVICES
Transcutaneous Electrical Nerve Stimulators
Table of Contents v
Neuromuscular Stimulators
Spinal Cord Stimulators and Peripheral Nerve Stimulators
PCAs and Intrathecal Pain Pumps
Other Miscellaneous devices
Cranial Electrotherapy Stimulation
Electrothermal and Electromagnetic Therapy
Thermography
Market Size and Growth
Markets by Region
CHAPTER SIX: ALTERNATE TREATMENT MODALITIES
Acupuncture
ETPS Neuropathic Acupuncture
Low Level Laser Light Therapy
Biofeedback
Relaxation
Music and Pain Relief
Wave Therapy
Acupressure
Massage Therapy
Natural Supplements in Pain Management
Bioelectromagnetism
Radiofrequency Technology
Cryoablation
CHAPTER SEVEN: ISSUES AND TRENDS
Overview
Barriers to Cancer Pain Management
Education
Chronic Pain and Work
Managed Care Pain Management
The Fifth Vital Sign
Use of Psychopharmacology in Chronic Pain
Use of Botulinum Neurotoxin
Research and Development
Table of Contents vi
Dyloject
Levadex
MoxDuo IR
Naproxcinod
Pennsaid 2%
Posidur
Remoxy
Zelrix
Zohydro ER
ARC-4558
BEMA Buprenorphine
NGX 1998
Sativex
ATx08-001
The Elderly
Oxycontin Issues
Constant Pain Phenomenon
Tylenol and Liver Damage
Pain Medication Treatment Confusion
Transporter Discovery
Marijuana and Pain Control
Abuse-Deterrent Painkillers
Drug Abuse and Pain Control
CHAPTER EIGHT: MARKET SUMMARY
Total Market Size and Forecast
Total Market Revenues by Region
Competitor Analysis
CHAPTER NINE: CORPORATE PROFILES
Abbott Laboratories
Actavis, Inc (formerly Watson Pharmaceuticals, Inc.)
AstraZeneca plc.
Baxter International, Inc.
BioDelivery Sciences International (BDSI)
Boehringer Ingelheim
Boston Scientific
Table of Contents vii
Bristol-Myers Squibb Company
DepoMed
DURECT Corporation
Eli Lilly & Co.
Endo Health Solutions Inc
GlaxoSmithKline plc
Grunenthal Group
Medtronic, Inc.
Merck & Co.
Novartis
Pain Therapeutics, Inc
Pfizer, Inc
Purdue Pharma
QRx Pharma
Sanofi
St. Jude Medical, Inc
TEVA Pharmaceuticals Industries, Ltd
The Medicines Company
Valeant Pharmaceuticals International, Inc.
Zogenix, Inc.
APPENDIX: COMPANY DIRECTORY
LIST OF EXHIBITS
CHAPTER ONE: EXECUTIVE SUMMARY
Summary Table: Total World Pain Management Market 2010-2017
Summary Figure: Total World Pain Management Market 2010-2017
CHAPTER TWO: INTRODUCTION AND OVERVIEW
Table 2-1: Most Commonly Used Pain Quality Descriptors
Table 2-2: Pharmacokinetics of Step I Analgesics by Product
Table 2-3: Step II Analgesics: Pharmacokinetics
Table 2-4: Step III Analgesics: Pharmacokinetics
Table 2-5: Worldwide Prevalence of Selected Pain Related Conditions (est. 2012)
CHAPTER THREE: TREATMENT MARKETS AND FORECASTS
Table 3-1: World Market for Burn Pain Management 2010-2017
Table 3-2: Regional Markets for Burn Pain Management 20010-2017
Figure 3-2: Regional Markets for Burn Pain Management 2010-2017
Table 3-3: World Market for Cancer Pain Management 2010-2017
Figure 3-3: World Market for Cancer Pain Management 2010-2017
Table 3-4: Regional Markets for Musculoskeletal Pain Management 2010-2017
Figure 3-4: Regional Markets for Musculoskeletal Pain Management 2010-2017
Table 3-5: The World Market for Dental/Facial Pain Management 2010-2017
Figure 3-5: The World Market for Dental/Facial Pain Management 2010-2017
Table 3-6: Regional Markets for Dental/Facial Pain Management 2010-2017
Figure 3-6: Regional Markets for Dental/Facial Pain Management 2010-2017
Table 3-7: World Market for Migraine Pain Management 2010-2017
Figure 3-7: World Market for Migraine Pain Management 2010-2017
Table 3-8: Regional Markets for Migraine Pain Management 2010-2017
Figure 3-8: Regional Markets for Migraine Pain Management 2010-2017
Table 3-9: World Market for Musculoskeletal Pain Management 2010-2017
Figure 3-9: World Market for Musculoskeletal Pain Management 2010-2017
Table 3-10: Regional Markets for Musculoskeletal Pain Management 2010-2017
Figure 3-10: Regional Markets for Musculoskeletal Pain Management 2010-2017
Table 3-11: World Market for Neuropathic Pain Management 2010-2017
Figure 3-11: World Market for Neuropathic Pain Management 2010-2017
Table 3-12: Regional Markets for Neuropathic Pain Management 2010-2017
Figure 3-12: Regional Markets for Neuropathic Pain Management 2010-2017
Table 3-13: World Market for Obstetrical Pain Management 2010-2017
Figure 3-13: World Market for Obstetrical Pain Management 2010-2017
Table 3-14: Regional Markets for Obstetrical Pain Management 2010-2017
Figure 3-14: Regional Markets for Obstetrical Pain Management 2010-2017
Table 3-15: The World Market for Pediatric Pain Management 2010-2017
Table 3-16: Regional Markets for Pediatric Pain Management 2010-2017
Figure 3-16: Regional Markets for Pediatric Pain Management 2010-2017
Table 3-17: World Market for Surgical and Trauma Pain Management 2010-2017
Table 3-18: Regional Markets for Surgical and Trauma Pain Management 2010-2017
Figure 3-18: Regional Markets for Surgical and Trauma Pain Management 2010-2017
CHAPTER FIVE: PAIN MANAGEMENT DEVICES
Table 5-1: World Market for Pain Management Devices 2010-2017
Figure 5-1: World Market for Pain Management Devices 2010-2017
Table 5-2: Regional Markets for Pain Management Devices 2010-2017
Figure 5-2: Regional Markets for Pain Management Devices 2010-2017
CHAPTER SIX: ALTERNATE TREATMENT MODALITIES
Table 6-1: Pain Management Supplements in Clinical Trials
CHAPTER SEVEN: ISSUES AND TRENDS
Table 7-1: Pain Management Products in Development 2012
CHAPTER EIGHT: MARKET SUMMARY
Table 8-1: Total World Pain Management Market 2010-2017
Figure 8-1: Total World Pain Management Market 2010-2017
Table 8-2: World Pain Management Market by Product Segment (Pain Type), 2010–2017
Table 8-3: Total Regional Markets for Pain Management 2010-2017
Figure 8-4: Total Regional Markets for Pain Management 2010-2017
Table 8-4: World Market for Top Pain Management Treatments Revenues and Segments of Participation by Major Areas of Participation 2012
Table 8-5: Revenues and Market Share by Company 2012 (some are estimated)
Figure 8-6: Market Share Percent by Company 2012
CHAPTER NINE: CORPORATE PROFILES
Figure 9-1: Abbott's Financial Performance, 2010-2012
Figure 9-2: Actavis’ Financial Performance, 2010-2012
Figure 9-3: AstraZeneca’s Financial Performance, 2010-2012
Figure 9-4: Baxter International’s Financial Performance, 2010-2012
Figure 9-6: Bristol-Myers Squibb’s Financial Performance, 2010-2012
Figure 9-7: Eli Lilly’s Financial Performance, 2010-2012
Figure 9-8: Endo Health Solutions’ Financial Performance, 2010-2012
Figure 9-9: GlaxoSmithKline’s Financial Performance, 2010-2012
Figure 9-10: Grunenthal’s Financial Performance, 2010-2012
Figure 9-11: Johnson and Johnson’s Financial Performance, 2010-2012
Figure 9-12: Medtronic’s Financial Performance, 2010-2012
Figure 9-13: Merck’s Financial Performance, 2010-2012
Figure 9-14: Novartis’ Financial Performance, 2010-2012
Figure 9-15: Pfizer’s Financial Performance, 2010-2012
Figure 9-16: Sanofi’s Financial Performance, 2010-2012
Figure 9-17: St Jude’s Financial Performance, 2010-2012
Figure 9-16: Teva’s Financial Performance, 2010-2012
Introduction
Scope and Methodology
Size and Growth of the Market
Issues and trends
Leading Competitors
CHAPTER TWO: INTRODUCTION AND OVERVIEW
Definition of Pain
Magnitude of Pain
Physiology of Pain
Transduction
Transmission
Pain Pathways
Types of Pain
Measurement of Pain
Treatment Modalities—Pharmacologic Management
Analgesic Ladder
Step I Drugs
Step II Drugs
Step III Drugs
Recommended Drug and Route
Administration Routes
Titration
Treatment Modalities—Non-pharmacologic Management
Cognitive-Behavioral Therapies
Multidisciplinary Pain Management
Demographics
CHAPTER THREE: TREATMENT MARKETS AND FORECASTS
Burn Pain
Overview of Top Products
Opiate Agonists—Natural Alkaloids
Opiate Agonists—Semisynthetic Analogs
Opiate Agonists—Synthetic Compounds
Market Size and Growth
Markets by Region
Cancer Pain
Breakthrough Cancer Pain
Overview of Top Products
Opiate Agonists- Natural Alkaloids
Opiate Agonists-Semisynthetic Analogs
Opiate Agonists- Synthetic Compounds
Phenylpiperdine Compounds
New and/or Innovative Products
Market Size and Growth
Markets by Region
Dental/Facial Pain
Overview of Top Products
Opiate Agonists- Natural Alkaloids
Opiate Agonists-Semisynthetic Analogs
Opiate Agonists- Synthetic Compounds
Opiate Agonist-Antagonists
Centrally-acting Synthetic Analgesic Compounds
New Products
Market Size and Growth
Markets by Region
Migraine Headache Pain
Overview of Top Products
Selective Serotonin Agonists
New and/or Innovative Products
Market Size and Growth
Markets by Region
Musculoskeletal Pain
Overview of Top Products
Phenylpiperidine Compounds
Cox-2 Inhibitors
Non-steroid Anti-inflammatory Drugs
Opioid Agonists- Natural Alkaloids
Hyaluronate Sodium Derivative
New and/or Innovative Products
Market Size and Growth
Markets by Region
Neuropathic Pain
Overview of Top Products
Antiseizure Drugs
Opiate Agonists- Natural Alkaloids
Opiate Agonists-Semi-Synthetic Analogs
Phenylpiperidine Compounds
New and/or Innovative Products
Market Size and Growth
Markets by Region
Obstetrical Pain
Overview of Top Products
Opiate Agonists—Synthetic Compounds
Opiate Agonist—Antagonists
Centrally Acting Synthetic Analgesic Compounds
Phenylpiperidine Compounds
Market Size and Growth
Markets by Region
Pediatric Pain
Overview of Top Products
Opiate Agonist-Antagonists
Indole Analogs
Opiate Agonists-Semisynthetic Analogs
Opiate Agonists- Natural Alkaloids
Market Size and Growth
Markets by Region
Surgical and Trauma Pain
Overview of Top Products
Opiate Agonists—Natural Alkaloids
Opiate Agonists—Semisynthetic Analogs
Opiate Agonists—Synthetic Compounds
Opiate Agonist—Antagonists
Centrally Acting Synthetic Analgesic Compounds
New and/or Innovative Product Approvals
Market Size and Growth
Markets by Region
CHAPTER FOUR: DRUG DELIVERY
Oral Drug Delivery
Parenteral Drug Delivery
Transdermal
Patient Controlled Analgesia
Intrathecal Implants
Electrotransport Drug Delivery
CHAPTER FIVE: PAIN MANAGEMENT DEVICES
Transcutaneous Electrical Nerve Stimulators
Table of Contents v
Neuromuscular Stimulators
Spinal Cord Stimulators and Peripheral Nerve Stimulators
PCAs and Intrathecal Pain Pumps
Other Miscellaneous devices
Cranial Electrotherapy Stimulation
Electrothermal and Electromagnetic Therapy
Thermography
Market Size and Growth
Markets by Region
CHAPTER SIX: ALTERNATE TREATMENT MODALITIES
Acupuncture
ETPS Neuropathic Acupuncture
Low Level Laser Light Therapy
Biofeedback
Relaxation
Music and Pain Relief
Wave Therapy
Acupressure
Massage Therapy
Natural Supplements in Pain Management
Bioelectromagnetism
Radiofrequency Technology
Cryoablation
CHAPTER SEVEN: ISSUES AND TRENDS
Overview
Barriers to Cancer Pain Management
Education
Chronic Pain and Work
Managed Care Pain Management
The Fifth Vital Sign
Use of Psychopharmacology in Chronic Pain
Use of Botulinum Neurotoxin
Research and Development
Table of Contents vi
Dyloject
Levadex
MoxDuo IR
Naproxcinod
Pennsaid 2%
Posidur
Remoxy
Zelrix
Zohydro ER
ARC-4558
BEMA Buprenorphine
NGX 1998
Sativex
ATx08-001
The Elderly
Oxycontin Issues
Constant Pain Phenomenon
Tylenol and Liver Damage
Pain Medication Treatment Confusion
Transporter Discovery
Marijuana and Pain Control
Abuse-Deterrent Painkillers
Drug Abuse and Pain Control
CHAPTER EIGHT: MARKET SUMMARY
Total Market Size and Forecast
Total Market Revenues by Region
Competitor Analysis
CHAPTER NINE: CORPORATE PROFILES
Abbott Laboratories
Actavis, Inc (formerly Watson Pharmaceuticals, Inc.)
AstraZeneca plc.
Baxter International, Inc.
BioDelivery Sciences International (BDSI)
Boehringer Ingelheim
Boston Scientific
Table of Contents vii
Bristol-Myers Squibb Company
DepoMed
DURECT Corporation
Eli Lilly & Co.
Endo Health Solutions Inc
GlaxoSmithKline plc
Grunenthal Group
Medtronic, Inc.
Merck & Co.
Novartis
Pain Therapeutics, Inc
Pfizer, Inc
Purdue Pharma
QRx Pharma
Sanofi
St. Jude Medical, Inc
TEVA Pharmaceuticals Industries, Ltd
The Medicines Company
Valeant Pharmaceuticals International, Inc.
Zogenix, Inc.
APPENDIX: COMPANY DIRECTORY
LIST OF EXHIBITS
CHAPTER ONE: EXECUTIVE SUMMARY
Summary Table: Total World Pain Management Market 2010-2017
Summary Figure: Total World Pain Management Market 2010-2017
CHAPTER TWO: INTRODUCTION AND OVERVIEW
Table 2-1: Most Commonly Used Pain Quality Descriptors
Table 2-2: Pharmacokinetics of Step I Analgesics by Product
Table 2-3: Step II Analgesics: Pharmacokinetics
Table 2-4: Step III Analgesics: Pharmacokinetics
Table 2-5: Worldwide Prevalence of Selected Pain Related Conditions (est. 2012)
CHAPTER THREE: TREATMENT MARKETS AND FORECASTS
Table 3-1: World Market for Burn Pain Management 2010-2017
Table 3-2: Regional Markets for Burn Pain Management 20010-2017
Figure 3-2: Regional Markets for Burn Pain Management 2010-2017
Table 3-3: World Market for Cancer Pain Management 2010-2017
Figure 3-3: World Market for Cancer Pain Management 2010-2017
Table 3-4: Regional Markets for Musculoskeletal Pain Management 2010-2017
Figure 3-4: Regional Markets for Musculoskeletal Pain Management 2010-2017
Table 3-5: The World Market for Dental/Facial Pain Management 2010-2017
Figure 3-5: The World Market for Dental/Facial Pain Management 2010-2017
Table 3-6: Regional Markets for Dental/Facial Pain Management 2010-2017
Figure 3-6: Regional Markets for Dental/Facial Pain Management 2010-2017
Table 3-7: World Market for Migraine Pain Management 2010-2017
Figure 3-7: World Market for Migraine Pain Management 2010-2017
Table 3-8: Regional Markets for Migraine Pain Management 2010-2017
Figure 3-8: Regional Markets for Migraine Pain Management 2010-2017
Table 3-9: World Market for Musculoskeletal Pain Management 2010-2017
Figure 3-9: World Market for Musculoskeletal Pain Management 2010-2017
Table 3-10: Regional Markets for Musculoskeletal Pain Management 2010-2017
Figure 3-10: Regional Markets for Musculoskeletal Pain Management 2010-2017
Table 3-11: World Market for Neuropathic Pain Management 2010-2017
Figure 3-11: World Market for Neuropathic Pain Management 2010-2017
Table 3-12: Regional Markets for Neuropathic Pain Management 2010-2017
Figure 3-12: Regional Markets for Neuropathic Pain Management 2010-2017
Table 3-13: World Market for Obstetrical Pain Management 2010-2017
Figure 3-13: World Market for Obstetrical Pain Management 2010-2017
Table 3-14: Regional Markets for Obstetrical Pain Management 2010-2017
Figure 3-14: Regional Markets for Obstetrical Pain Management 2010-2017
Table 3-15: The World Market for Pediatric Pain Management 2010-2017
Table 3-16: Regional Markets for Pediatric Pain Management 2010-2017
Figure 3-16: Regional Markets for Pediatric Pain Management 2010-2017
Table 3-17: World Market for Surgical and Trauma Pain Management 2010-2017
Table 3-18: Regional Markets for Surgical and Trauma Pain Management 2010-2017
Figure 3-18: Regional Markets for Surgical and Trauma Pain Management 2010-2017
CHAPTER FIVE: PAIN MANAGEMENT DEVICES
Table 5-1: World Market for Pain Management Devices 2010-2017
Figure 5-1: World Market for Pain Management Devices 2010-2017
Table 5-2: Regional Markets for Pain Management Devices 2010-2017
Figure 5-2: Regional Markets for Pain Management Devices 2010-2017
CHAPTER SIX: ALTERNATE TREATMENT MODALITIES
Table 6-1: Pain Management Supplements in Clinical Trials
CHAPTER SEVEN: ISSUES AND TRENDS
Table 7-1: Pain Management Products in Development 2012
CHAPTER EIGHT: MARKET SUMMARY
Table 8-1: Total World Pain Management Market 2010-2017
Figure 8-1: Total World Pain Management Market 2010-2017
Table 8-2: World Pain Management Market by Product Segment (Pain Type), 2010–2017
Table 8-3: Total Regional Markets for Pain Management 2010-2017
Figure 8-4: Total Regional Markets for Pain Management 2010-2017
Table 8-4: World Market for Top Pain Management Treatments Revenues and Segments of Participation by Major Areas of Participation 2012
Table 8-5: Revenues and Market Share by Company 2012 (some are estimated)
Figure 8-6: Market Share Percent by Company 2012
CHAPTER NINE: CORPORATE PROFILES
Figure 9-1: Abbott's Financial Performance, 2010-2012
Figure 9-2: Actavis’ Financial Performance, 2010-2012
Figure 9-3: AstraZeneca’s Financial Performance, 2010-2012
Figure 9-4: Baxter International’s Financial Performance, 2010-2012
Figure 9-6: Bristol-Myers Squibb’s Financial Performance, 2010-2012
Figure 9-7: Eli Lilly’s Financial Performance, 2010-2012
Figure 9-8: Endo Health Solutions’ Financial Performance, 2010-2012
Figure 9-9: GlaxoSmithKline’s Financial Performance, 2010-2012
Figure 9-10: Grunenthal’s Financial Performance, 2010-2012
Figure 9-11: Johnson and Johnson’s Financial Performance, 2010-2012
Figure 9-12: Medtronic’s Financial Performance, 2010-2012
Figure 9-13: Merck’s Financial Performance, 2010-2012
Figure 9-14: Novartis’ Financial Performance, 2010-2012
Figure 9-15: Pfizer’s Financial Performance, 2010-2012
Figure 9-16: Sanofi’s Financial Performance, 2010-2012
Figure 9-17: St Jude’s Financial Performance, 2010-2012
Figure 9-16: Teva’s Financial Performance, 2010-2012
Once the nociceptive signal arrives in the CNS, it is processed within thedorsal horn of the spinal cord. This processing includes releasing neurotransmittersfrom the PAN into the synaptic cleft and binding neurotransmitters to receptors onnearby cell bodies and dendrites of cells that may be located elsewhere in the dorsalhorn. Some of these PAN neurotransmitters produce activation when bound toreceptors whereas other inhibits activation of nearby cells. Cells excited by PANinput release other neurotransmitters, which increases the complexity of theneurochemical communication occurring within the dorsal horn. The effects of thecomplex neurotransmitter release can facilitate or inhibit transmission of nociceptivestimuli.
Most projection cells send axons to the brain on the opposite side of the body.They receive excitatory and inhibitory messages, the net sum of which determineswhether the PSN message will be transmitted to the brain.
Interneurons can be either excitatory or inhibitory. They communicate withother lamina II cells, located within one or two spinal segments, and with dendritesfrom cells located in laminae I, III, IV, and V. The concept of excitatory andinhibitory interneurons is important because it helps to explain why some nonpharmacologictherapies are effective. Although the exact mechanisms have not beendetermined, it is known that simulation of large sensory fibers can have an inhibitoryeffect on cells that project nociceptive signals to the brain. TENS and massage areexamples of methods by which smaller, less rapidly conducting fibers can beactivated by non-noxious stimuli. All of these methods are known to inhibittransmission of nociceptive stimuli.
